Pentoxifylline, 20 mg/ml concentrate 5 ml 10 pcs

Microcirculation improving agent, angioprotector, dimethylxanthine derivative. Pentoxifylline reduces blood viscosity, causes platelet disaggregation, increases the elasticity of red blood cells (due to the effect on pathologically altered red blood cell deformability), improves microcirculation and increases the oxygen concentration in tissues. Increases the concentration of cAMP in platelets and ATP in erythrocytes with simultaneous saturation of the energy potential, which in turn leads to vasodilation, reduction of OPPS, increase in stroke volume and minute blood volume without significant change in HR.

Dilating the coronary arteries, it increases oxygen delivery to the myocardium, expanding the pulmonary vessels, improves blood oxygenation. Increases the tone of the respiratory muscles (intercostal muscles and diaphragm).

Injection by injection, along with the above action, leads to increased collateral circulation, increasing the volume of blood flowing through the unit section.

Enhances the concentration of ATP in the brain, favorably influences the bioelectrical activity of the CNS. Improves microcirculation in areas of compromised blood supply.

In cases of occlusive lesions of the peripheral arteries (“intermittent” claudication) it leads to the extension of walking distance, the elimination of cramps of the calf muscles and pain at rest.

After oral administration it is well absorbed from the gastrointestinal tract. Minor metabolism during “first passage” through the liver is noted. It binds to erythrocyte membranes. It undergoes biotransformation first in red blood cells and then in the liver. Some metabolites are active. T_1/2 from plasma is 0.4-0.8 hours for unchanged substance, 1-1.6 hours for metabolites. After 24 hours most of the dose is excreted in the urine as metabolites, a smaller part (about 4%) – through the intestine.

The excretion of pentoxifylline is decreased in elderly patients and in liver disease.

Indications

Vascular lesions in diabetes mellitus, Impaired hearing, Impaired attention and memory, Diabetic retinopathy, Trophic ulcers, Raynaud’s disease, Cramps of the calf muscles, Dizziness, Stroke sequelae, Vascular eye disease, Impaired cerebral circulation, Atherosclerosis, Frostbite

After oral administration it is well absorbed from the GI tract. Minor metabolism during “first passage” through the liver is noted. Binds to erythrocyte membranes. It undergoes biotransformation first in red blood cells and then in the liver. Some metabolites are active. T_1/2 from plasma is 0.4-0.8 hours for unchanged substance, 1-1.6 hours for metabolites. After 24 hours most of the dose is excreted in the urine as metabolites, a smaller part (about 4%) – through the intestine.

The excretion of pentoxifylline is decreased in elderly patients and in liver disease.

Active ingredient

Pentoxifylline

How to take, the dosage

It is administered v/a (by jet or drip), v/v (by jet or drip), v/m, orally. The dose and treatment regimen are determined individually.

Interaction

With caution use in BP lability (tendency to arterial hypotension), chronic heart failure, gastric and duodenal ulcer (for oral administration), after recent surgical interventions, in hepatic and/or renal failure, in children and adolescents under 18 years (effectiveness and safety are not studied).

In case of impaired renal function or severe hepatic impairment, correction of the dosing regimen of pentoxifylline is required.

The BP should be monitored during treatment.

In concomitant use with antihypertensive agents, insulin, oral hypoglycemic agents may require reduction of the dose of pentoxifylline.

When used concomitantly with anticoagulants, blood clotting parameters should be carefully monitored.

Special Instructions

With caution use in BP lability (tendency to arterial hypotension), chronic heart failure, gastric and duodenal ulcer (for oral administration), after recent surgical interventions, in hepatic and/or renal failure, in children and adolescents under 18 years (effectiveness and safety are not studied).

In case of impaired renal function or severe hepatic impairment, correction of the dosing regimen of pentoxifylline is required.

The BP should be monitored during treatment.

In concomitant use with antihypertensive agents, insulin, oral hypoglycemic agents may require reduction of the dose of pentoxifylline.

When used concomitantly with anticoagulants, blood clotting parameters should be carefully monitored.

Contraindications

Acute myocardial infarction, porphyria, massive bleeding, hemorrhagic stroke, retinal hemorrhage, pregnancy, lactation. For intravenous administration (optional) – arrhythmias, marked atherosclerosis of coronary or cerebral arteries, uncontrolled arterial hypotension.

High sensitivity to pentoxifylline and other xanthine derivatives.

Side effects

CNS: headache, dizziness; anxiety, sleep disorders; seizures.

Similarities

Vasonit, Trental, Trental 400, Pentoxifylline, Trental 100, Pentoxifylline-SZ